Comparing needle sizes for better prostate cancer detection

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study evaluates whether using a larger caliber (16G) needle for transperineal MRI-targeted prostate biopsies improves the detection rate of prostate cancer compared to a smaller caliber (18G) needle. The research focuses on assessing the diagnostic capabilities of each needle size while monitoring for any differences in side effects or complications. Patients with suspected prostate cancer will undergo biopsies using both needle sizes to determine which is more effective in identifying cancerous lesions.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Clinical suspicion of prostate cancer (presence of elevated prostatic specific antigen and/or suspicious digital rectal examination);
* Presence of at least one suspicious prostate lesion on MRI (Prostate Imaging-Reporting and Data System ≥ 3) according to the Prostate Imaging-Reporting and Data System v2.1 performed before Magnetic Resonance Imaging/transrectal ultrasound fusion biopsy.

Exclusion Criteria:

* Patients under active surveillance or with a previous diagnosis of prostate neoplasia prior to biopsy.
* Previous radiotherapy to the prostate for neoplasia.

Where it's running

• Urology Unit - Padua University Hospital
  Padua, Italy, Italy Recruiting

Study contacts

• Principal investigator: Fabio Zattoni, MD, PhD — Department of Surgery, Oncology and Gastroenterology, Urology Clinic, University of Padua, Padova,
• Study coordinator: Fabio F. Zattoni, MD, PhD
• Email: fabio.zattoni@unipd.it
• Phone: 0498212730

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• 68Ga-XMFH01 PET/FL imaging to guide prostate cancer surgery

  This study tests a new dual-modality imaging probe, 68Ga-XMFH01, to preoperatively detect prostate cancer and guide the surgeon with fluorescence during operations in adults with newly diagnosed prostate cancer.

  Recruiting The First Affiliated Hospital of Xiamen University · Xiamen, Fujian · NCT07885423

• Hugo Robotic Prostatectomy in an Ambulatory Surgery Center

  This study tests the use of the Hugo robotic system for prostate removal in adult men treated at an outpatient surgical center.

  Recruiting Central Ohio Urology Group · Columbus, Ohio · NCT07875192

• Adaptive intraoperative biopsy system for prostate cancer using imaging and metabolic feedback

  Aiming to test a smart biopsy approach that combines preoperative imaging with real-time metabolic signals to guide where to take prostate biopsy cores for better precision in men suspected of prostate cancer.

  Recruiting at 4 sites Shanghai Zhongshan Hospital · Shanghai and 3 other locations · NCT07856017

• miRNA panel test to help diagnose prostate cancer

  A blood test using a microRNA panel is being tested to help diagnose prostate cancer in men who are suspected of having the disease.

  Recruiting RenJi Hospital · Shanghai · NCT07755592

• Testing 68Ga-NYM032 PET/CT in men with newly diagnosed prostate cancer

  This study tests a new PSMA-targeted PET/CT imaging agent to see if it safely and accurately locates cancer in men who have just been diagnosed with prostate cancer and are planned for surgery.

  Recruiting at 2 sites Phase 3 Norroy Bioscience Co., LTD · Nanjing, Jiangsu and 1 other locations · NCT07615101

• Multi-Modal Imaging and Digital Pathology to Predict Clinically Significant Prostate Cancer

  A multi-center study tests a deep learning model that combines MRI, ultrasound, and digital pathology to see if it can predict clinically significant prostate cancer non-invasively and help guide biopsies.

  Recruiting Guangxi Medical University · Liuzhou, Guangxi · NCT07614256

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.